myeloMATCH
myeloMATCH is a US-wide master trial that sequences every new leukaemia within days and routes the patient to the right experimental arm, then re-routes them as MRD results come in.
Launched 2024 across ~200 sites. Rapid central genomics (results in 72 hours) and MRD assessments at each 'tier' allow patients to move between sub-studies (e.g., FLT3, TP53, NPM1, older-unfit cohorts) testing venetoclax, menin inhibitors, FLT3 inhibitors, magrolimab successors, and CPX-351. The infrastructure model for precision leukaemia trials.
Pages like this
not linked directly; found by shared links- TrialCPX-351 Study 301
Shares CPX-351 (liposomal daunorubicin-cytarabine), Acute myeloid leukaemia.
- IdeaA perpetual platform trial in every major cancer, funded as infrastructure
Shares Basket, umbrella, and platform trials, Too many combinations to test, National Cancer Institute (NIH), Trial design, endpoints and cost.
- IdeaA standing platform trial that assigns treatment by how the tumour escaped
Shares Basket, umbrella, and platform trials, Comprehensive genomic profiling, Trial design, endpoints and cost.
- IdeaA standing platform trial for every major cancer, funded as infrastructure
Shares Basket, umbrella, and platform trials, Too many combinations to test, Trial design, endpoints and cost.
- IdeaMRD-guided treatment duration in CLL
Shares NGS-based MRD (clonoSEQ and molecular MRD), MRD-negative complete remission, Venetoclax.
- IdeaLet the trial learn: response-adaptive allocation across many combination arms
Shares Basket, umbrella, and platform trials, Too many combinations to test, Trial design, endpoints and cost.
- IdeaOne standing umbrella trial for all rare cancers in a country
Shares Basket, umbrella, and platform trials, National Cancer Institute (NIH), Comprehensive genomic profiling, Trial design, endpoints and cost.
- CompanyKura Oncology
Shares Ziftomenib, Acute myeloid leukaemia.